BPC June 22 update

Athira ATHA Phase 2 Alziemer’s trial fail; Precision DTIL Back to back NVS deal and offering

Pre-Market Updates

Yesterday's BIOrdle ticker was APVO. Aptevo Therapeutics Inc. (NASDAQ: APVO) is a clinical-stage biotechnology developing immuno-oncology therapeutics. Aptevo has a catalyst planned for mid-2022 for its Phase 1b trial of APVO436 to treat acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Shares closed yesterday up 6% at $3.70.

__________________________

Athira Pharma, Inc. (NASDAQ: ATHA) announced topline results from its Phase 2 ACT-AD trial of fosgonimeton (ATH-1017) to treat mild-to-moderate Alzheimer's disease (AD). The trial did not meet its primary endpoint of change in biomarker ERP P300 latency.

Codex DNA (NASDAQ: DNAY) shares are trading up during the premarket following an SEC form 4 from Codex COO Esser Eric Eugene was filed on June 15, 2022. The COO acquired 225 thousand stock options at $2.71 per share price.

Precision BioSciences, Inc. (NASDAQ: DTIL) announced two changes to its cash runaway guidance after it entered into a collaboration and license agreement with Novartis Pharma AG (NYSE: NVS) for $75 million upfront and up to $1.4 billion in milestone to develop a in vivo gene therapy treatment for sickle cell disease and beta thalassemia. Precision also announced an offering of 35,971,224 shares at $1.39 per share for gross proceeds of approximately $50 million.

Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) announced top line results of its Phase 2 INSPIRE trial of Zygel to treat symptoms of 22q11.2 deletion syndrome. The trial met multiple efficacy assessments, and Zynerba is planning a meeting with the FDA to discuss the next steps in development.

Rockwell Medical Inc (NASDAQ: RMTI) announced the appointment of Mark Strobeck as President And Chief Executive Officer, effective July 1, 2022.

BridgeBio Pharma, Inc. (NASDAQ: BBIO) released data from the first two patients from its Phase 1/2 clinical trial of BBP-812 to treat Canavan disease. Initial pharmacodynamic results noted decreases in N-acetylaspartate (NAA) in the brain and urine.

ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced that the FDA approved its Abbreviated New Drug Application (ANDA) for Clorazepate Dipotassium Tablets, a generic version of the Reference Listed Drug (RLD) Tranxene.

Pre-Market Advancers

CompanyPriceChange
TALS
Talaris Therapeutics Inc.
$1.01 +1.01  +100%
AKUS
Akouos Inc.
$1.01 +1.01  +100%
QNRX
Quoin Pharmaceuticals Ltd.
$1.01 +1.01  +100%
BBI
Brickell Biotech, Inc.
$1.01 +1.01  +100%
AKBA
Akebia Therapeutics Inc.
$1.01 +1.01  +100%
ALNA
Allena Pharmaceuticals Inc.
$1.01 +1.01  +100%
PRVB
Provention Bio Inc.
$1.01 +1.01  +100%
IVC
Invacare Corporation
$1.01 +1.01  +100%
ENSC
Ensysce Biosciences Inc.
$1.01 +1.01  +100%
BNTC
Benitec Biopharma Inc.
$1.01 +1.01  +100%

Pre-Market Decliners

CompanyPriceChange
CADL
Candel Therapeutics Inc.
$1.01 -1.01  -100%
CLVS
Clovis Oncology Inc.
$1.01 -1.01  -100%
ENDP
Endo International plc
$1.01 -1.01  -100%
TYRA
Tyra Biosciences Inc.
$1.01 -1.01  -100%
CTKB
Cytek Biosciences Inc.
$1.01 -1.01  -100%
BLTE
Belite Bio Inc
$1.01 -1.01  -100%
MREO
Mereo BioPharma Group plc
$1.01 -1.01  -100%
CRTX
Cortexyme Inc.
$1.01 -1.01  -100%
PULM
Pulmatrix Inc.
$1.01 -1.01  -100%
RXST
RxSight Inc.
$1.01 -1.01  -100%